What does AALST UROLOGY GROUP do?

AALST UROLOGY GROUP is a specialist medical practice in Dilbeek. Private Limited, started on 11 August 2021, 1 establishment.

What is the address of AALST UROLOGY GROUP?

The registered office of AALST UROLOGY GROUP is located at Bremstraat 6, 1702 Dilbeek.

Is AALST UROLOGY GROUP still active?

Yes. According to the CBE (29 September 2026) AALST UROLOGY GROUP is active, legal situation “Normale toestand”, started on 11 August 2021.

Is AALST UROLOGY GROUP registered on Peppol?

Yes, AALST UROLOGY GROUP is registered on the Peppol network with ID 0208:0772453659.

What is the enterprise number of AALST UROLOGY GROUP?

The enterprise number of AALST UROLOGY GROUP is BE0772453659.

When was AALST UROLOGY GROUP founded?

AALST UROLOGY GROUP was founded on 11 August 2021.

Who are the directors of AALST UROLOGY GROUP?

According to the 2025 annual accounts, the directors of AALST UROLOGY GROUP are: Peter Schatteman.

Is AALST UROLOGY GROUP a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 11 August 2021; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did AALST UROLOGY GROUP make in 2025?

AALST UROLOGY GROUP posted a profit after taxes of € 10,000 in financial year 2025.

What is the revenue of AALST UROLOGY GROUP?

As a small company, AALST UROLOGY GROUP is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 37,988.

AALST UROLOGY GROUP (Private Limited) - Dilbeek

Dossier AALST UROLOGY GROUP, printed on 29 September 2026 from databakkes.be/en/0772453659/aalst-urology-group. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

AALST UROLOGY GROUP from Dilbeek, company number BE0772453659, closed financial year 2025 with a result of € 10,000 after tax. For that financial year AALST UROLOGY GROUP recorded a gross margin of € 37,988 and equity of € 50,011. Compared with financial year 2024, the result moved from € 10,005 to € 10,000. The company is profitable. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 6, 2026.

What it is worth Growing

€ 50,011

▲ 25% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 10,000

Profit after tax over the fiscal year.

Cash in the bank

€ 531,667

▲ 6% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 40,011.

Debts at end 2025

Bank debt

€ 237

▲ 25% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 1.8 million

▲ 25% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 3,350

▼ 96% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 24,200 Gross margin 2022: € 24,200 First fiscal year in the series	€ 21,640 Gross margin 2023: € 21,640 ▼ 11% vs 2022 (€ 24,200) Unfavourable step	€ 104,201 Gross margin 2024: € 104,201 ▲ € 82,561 vs 2023 (€ 21,640) Favourable step	€ 37,988 Gross margin 2025: € 37,988 ▼ 64% vs 2024 (€ 104,201) Unfavourable step	▼ 64%
Profit after taxes	€ 10,001 Profit after taxes 2022: € 10,001 First fiscal year in the series	€ 10,004 Profit after taxes 2023: € 10,004 Unchanged (€ 10,001) Favourable step	€ 10,005 Profit after taxes 2024: € 10,005 Unchanged (€ 10,004) Favourable step	€ 10,000 Profit after taxes 2025: € 10,000 Unchanged (€ 10,005) Unfavourable step
Equity	€ 20,001 Equity 2022: € 20,001 First fiscal year in the series	€ 30,005 Equity 2023: € 30,005 ▲ 50% vs 2022 (€ 20,001) Favourable step	€ 40,010 Equity 2024: € 40,010 ▲ 33% vs 2023 (€ 30,005) Favourable step	€ 50,011 Equity 2025: € 50,011 ▲ 25% vs 2024 (€ 40,010) Favourable step	▲ 25%
Total debts	€ 1,269,160 Total debts 2022: € 1,269,160 First fiscal year in the series	€ 1,051,214 Total debts 2023: € 1,051,214 ▼ 17% vs 2022 (€ 1,269,160) Favourable step	€ 1,574,750 Total debts 2024: € 1,574,750 ▲ 50% vs 2023 (€ 1,051,214) Unfavourable step	€ 2,149,704 Total debts 2025: € 2,149,704 ▲ 37% vs 2024 (€ 1,574,750) Unfavourable step	▲ 37%
Cash	€ 212,978 Cash 2022: € 212,978 First fiscal year in the series	€ 239,339 Cash 2023: € 239,339 ▲ 12% vs 2022 (€ 212,978) Favourable step	€ 499,369 Cash 2024: € 499,369 ▲ 109% vs 2023 (€ 239,339) Favourable step	€ 531,667 Cash 2025: € 531,667 ▲ 6% vs 2024 (€ 499,369) Favourable step	▲ 6%
Retained profit	€ 10,001 Retained profit 2022: € 10,001 First fiscal year in the series	€ 20,005 Retained profit 2023: € 20,005 ▲ 100% vs 2022 (€ 10,001) Favourable step	€ 30,010 Retained profit 2024: € 30,010 ▲ 50% vs 2023 (€ 20,005) Favourable step	€ 40,011 Retained profit 2025: € 40,011 ▲ 33% vs 2024 (€ 30,010) Favourable step	▲ 33%
Bank debt	€ 185 Bank debt 2022: € 185 First fiscal year in the series	€ 188 Bank debt 2023: € 188 ▲ 2% vs 2022 (€ 185) Unfavourable step	€ 189 Bank debt 2024: € 189 ▲ 1% vs 2023 (€ 188) Unfavourable step	€ 237 Bank debt 2025: € 237 ▲ 25% vs 2024 (€ 189) Unfavourable step	▲ 25%
Balance sheet total	€ 1,289,161 Balance sheet total 2022: € 1,289,161 First fiscal year in the series	€ 1,081,219 Balance sheet total 2023: € 1,081,219 ▼ 16% vs 2022 (€ 1,289,161) Unchanged	€ 1,614,761 Balance sheet total 2024: € 1,614,761 ▲ 49% vs 2023 (€ 1,081,219) Unchanged	€ 2,199,715 Balance sheet total 2025: € 2,199,715 ▲ 36% vs 2024 (€ 1,614,761) Unchanged	▲ 36%

Key figures of AALST UROLOGY GROUP, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to AALST UROLOGY GROUP?

What happened at AALST UROLOGY GROUP in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 6, 2026 New annual accounts for financial year 2025: profit of € 10,000. Source: NBB ↗
Aug 11, 2021 New establishment in Dilbeek. KBO
2021 Peter Schatteman became a director. NBB
Aug 11, 2021 Start of the company according to the CBE. KBO

In short

From € 10,001 profit in 2022 to € 10,000 profit in 2025.

Paid € 28,706 in corporate taxes since 2022.

Best year ever: 2024, with € 10,005 profit.

Original PDFs at the National Bank ↗

A new publication or filing at AALST UROLOGY GROUP? We notify you, reason included.

Follow AALST UROLOGY GROUP

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

DOKTER PETER SCHATTEMAN-UROLOGIE 20%

Dr. De Naeyer Geert 20%

DR.F.D'HONDT - UROLOGIE 20%

DOKTER BERNARD RAPPE 9.1%

The stake of DOKTER PETER SCHATTEMAN-UROLOGIE, Dr. De Naeyer Geert, DR.F.D'HONDT - UROLOGIE, DOKTER BERNARD RAPPE comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

AALST UROLOGY GROUP

Behind AALST UROLOGY GROUP is Peter Schatteman. The shares are held by DOKTER PETER SCHATTEMAN-UROLOGIE (20%), Dr. De Naeyer Geert (20%), DR.F.D'HONDT - UROLOGIE (20%) and DOKTER BERNARD RAPPE (9.1%).

See the full network in the app